{"article_url":"https://newsverum.com/de/news/everest-medicines-first-patient-dosed-ascend-phase-2b-vis-101-wet-amd-2026","block":{"description":{"ar":"معايير مختارة لتجربة ASCEND للمرحلة 2b وبيانات ديمومة المرحلة 2a وتقديرات انتشار التنكس البقعي التي أوردتها إيفريست ميديسينز.","de":"Ausgewählte Parameter der Phase-2b-Studie ASCEND, Phase-2a-Daten zur Wirkdauer und epidemiologische Schätzungen von Everest Medicines.","en":"Selected ASCEND Phase 2b trial parameters, Phase 2a durability data and regional wet AMD prevalence estimates cited by Everest Medicines.","es":"Parámetros seleccionados del ensayo de fase 2b ASCEND, datos de durabilidad de fase 2a y estimaciones epidemiológicas citadas por Everest Medicines.","fr":"Paramètres sélectionnés de l'essai de phase 2b ASCEND, données de durabilité de phase 2a et estimations épidémiologiques citées par Everest Medicines.","pt":"Parâmetros selecionados do ensaio de fase 2b ASCEND, dados de durabilidade de fase 2a e estimativas epidemiológicas citadas pela Everest Medicines.","tr":"Everest Medicines tarafından aktarılan seçilmiş ASCEND Faz 2b parametreleri, Faz 2a dayanıklılık verileri ve bölgesel yaş tip AMD prevalans tahminleri."},"id":"reported-figures","items":[{"basis":"target","label":{"ar":"العدد المخطط للمرضى في تجربة ASCEND للمرحلة 2b في الصين","de":"Geplante Teilnehmerzahl in der Phase-2b-Studie ASCEND in China","en":"Planned enrolment in ASCEND Phase 2b wet AMD trial in China","es":"Reclutamiento previsto en el ensayo de fase 2b ASCEND en China","fr":"Effectif prévu dans l'essai de phase 2b ASCEND en Chine","pt":"Recrutamento previsto no ensaio de fase 2b ASCEND na China","tr":"Çin'deki ASCEND Faz 2b yaş tip AMD çalışmasında planlanan hasta sayısı"},"measure":{"aggregation":"stock","frequency":"irregular","geography":"china","id":"g20261120-d7-everest-1","periodRole":"announcement-date","unitCode":"count"},"period":"2026-11-20","unit":"patients","value":244,"valueQualifier":"approximate"},{"basis":"observed","label":{"ar":"أسبوع تقييم نقطة النهاية الأساسية للفعالية في دراسة ASCEND","de":"Bewertungszeitpunkt des primären Wirksamkeitsendpunkts in ASCEND","en":"Primary efficacy endpoint assessment time in ASCEND","es":"Semana de evaluación del criterio principal de eficacia en ASCEND","fr":"Semaine d'évaluation du critère principal d'efficacité dans ASCEND","pt":"Semana de avaliação do parâmetro principal de eficácia no ASCEND","tr":"ASCEND çalışmasında birincil etkinlik değerlendirme haftası"},"measure":{"aggregation":"unspecified","frequency":"irregular","geography":"china","id":"g20261120-d7-everest-2","periodRole":"announcement-date","unitCode":"week"},"period":"2026-11-20","unit":"weeks","value":36},{"basis":"observed","label":{"ar":"نسبة المرضى غير المحتاجين لإعادة العلاج بعد 6 أشهر في مجموعة 6 ملغ بالمرحلة 2a","de":"Anteil der 6-mg-Kohorte in Phase 2a ohne erneute Behandlung nach 6 Monaten","en":"Phase 2a 6 mg treatment-naïve cohort retreatment-free at 6 months","es":"Porcentaje de la cohorte 6 mg de fase 2a sin retratamiento a los 6 meses","fr":"Part de la cohorte 6 mg de phase 2a sans retraitement à 6 mois","pt":"Percentagem da coorte de 6 mg na fase 2a sem retratamento aos 6 meses","tr":"Faz 2a 6 mg tedavi görmemiş grupta 6. ayda yeniden tedavi gerektirmeyen oran"},"measure":{"aggregation":"rate","frequency":"irregular","geography":"china","id":"g20261120-d7-everest-3","periodRole":"announcement-date","unitCode":"percent"},"period":"2026-11-20","unit":"percent","value":50,"valueQualifier":"approximate"},{"basis":"estimate","label":{"ar":"العدد السنوي المقدر للحالات الجديدة من التنكس البقعي والوذمة السكرية في الصين","de":"Geschätzte jährliche Neuerkrankungen an AMD und DMÖ in China","en":"Estimated annual new AMD and DME cases in China","es":"Casos nuevos anuales estimados de DMAE y EMD en China","fr":"Nombre annuel estimé de nouveaux cas de DMLA et d'OMD en Chine","pt":"Novos casos anuais estimados de DMRI e EMD na China","tr":"Çin'de tahmini yıllık yeni AMD ve DME vaka sayısı"},"measure":{"aggregation":"flow","frequency":"irregular","geography":"china","id":"g20261120-d7-everest-4","periodRole":"announcement-date","unitCode":"count"},"period":"2026-11-20","unit":"cases","value":600000,"valueQualifier":"approximate"},{"basis":"estimate","label":{"ar":"العدد المقدر لمرضى التنكس البقعي والوذمة السكرية المتلقين للعلاج حالياً في الصين","de":"Geschätzte Zahl derzeit behandelter AMD- und DMÖ-Patienten in China","en":"Estimated AMD and DME patients currently receiving treatment in China","es":"Pacientes estimados con DMAE y EMD que reciben tratamiento actualmente en China","fr":"Nombre estimé de patients atteints de DMLA et d'OMD actuellement traités en Chine","pt":"Doentes estimados com DMRI e EMD atualmente em tratamento na China","tr":"Çin'de halen tedavi alan tahmini AMD ve DME hasta sayısı"},"measure":{"aggregation":"stock","frequency":"irregular","geography":"china","id":"g20261120-d7-everest-5","periodRole":"announcement-date","unitCode":"count"},"period":"2026-11-20","unit":"patients","value":500000,"valueQualifier":"approximate"}],"methodology":{"ar":"تحتفظ الأرقام بتصميم الدراسة والسكان والنطاق والتعريفات التي يحددها المصدر، وتُصنف الأهداف وتقديرات الانتشار بحسب أساسها.","de":"Die Zahlen behalten Studiendesign, Bezugsgruppe, Umfang und Definitionen der Quelle bei. Ziele und Schätzungen sind nach ihrer Grundlage gekennzeichnet.","en":"Figures retain the source's stated trial design, population, scope and definitions. Targets and prevalence estimates are labeled by basis. No missing value is inferred.","es":"Las cifras conservan el diseño, la población, el alcance y las definiciones indicados por la fuente. Objetivos y estimaciones se identifican según su base.","fr":"Les chiffres conservent le protocole, la population, le périmètre et les définitions indiqués par la source. Objectifs et estimations sont qualifiés selon leur base.","pt":"Os valores mantêm o desenho, a população, o âmbito e as definições indicados pela fonte. Metas e estimativas são identificadas segundo a respetiva base.","tr":"Rakamlar kaynağın belirttiği çalışma tasarımı, nüfus, kapsam ve tanımları korur. Hedefler ve prevalans tahminleri dayanaklarına göre etiketlenir. Eksik değerler çıkarımla tamamlanmaz."},"sourceUrls":["https://www.prnewswire.com/apac/news-releases/everest-medicines-announces-first-patient-dosed-in-ascend-phase-2b-trial-of-vis-101-in-wet-amd-302946504.html"],"title":{"ar":"الأرقام الرئيسية المعلنة","de":"Wichtige gemeldete Kennzahlen","en":"Key reported figures","es":"Cifras clave comunicadas","fr":"Principaux chiffres déclarés","pt":"Principais valores reportados","tr":"Bildirilen temel rakamlar"},"type":"metrics","updatedAt":"2026-11-20T14:30:00Z"},"version":1}
